NR1H4 and metabolic dysfunction-associated steatotic liver disease: Considering the preclinical findings supporting the therapeutic potential of FXR agonists in the regulation of glucose and lipid metabolism, a phase IIa study was designed to test OCA in patients with type 2 diabetes and NAFLD [52].